Can a daily shot of IL-2 tame chronic GVHD?
NCT ID NCT01366092
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether daily low-dose injections of interleukin-2 (IL-2) can help control chronic graft-versus-host disease (cGVHD) in 35 people who did not respond to steroids. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack the recipient's body. The study aims to see if IL-2 can reduce cGVHD symptoms and allow patients to lower their steroid use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Interleukin-2 (IL-2)
- What this could lead to
- If it works, this could offer a new way to control chronic GVHD without high-dose steroids, potentially improving quality of life for transplant recipients.
- What could go wrong
- This is a small, early-phase trial with only 35 participants. The treatment may not work for everyone, and side effects from IL-2 are possible. Results need confirmation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02214, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can meditation tame the Long-Term side effects of a stem cell transplant?
- Could a liquid form of a Graft-Versus-Host disease drug be as effective as the pill?
- Scientists map immune battlefield in chronic GVHD tissue
- Could a rheumatoid arthritis drug tame chronic GVHD and cut steroid use?
- Could an arthritis drug tame a tough transplant complication?
- New hope for teens with chronic Graft-Versus-Host disease: belumosudil under study